Meeting
2020 ASCO Virtual Scientific Program
Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).
Authors
Martin Edelman
Fox Chase Cancer Center, Philadelphia, PA
Martin Edelman , Aaron Elliott Lisberg , Marianna Koczywas , Ben C. Creelan , Amanda Seiz , Eric Lutz , Lakshmi Rudraraju , Elizabeth DeOliveria , Monil Shah , Kim Noonan , Melissa Lynne Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04069936
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9630)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9630
Abstract #
TPS9630
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2017 ASCO Annual Meeting
Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.
First Author: Deborah Jean Lee Wong
Poster
2022 ASCO Annual Meeting
Merkel polyoma virus specific T-cell receptor transgenic T-cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma.
First Author: Joshua Veatch
Poster
2021 ASCO Annual Meeting
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
First Author: Mariam Jamal-Hanjani